JP2011505349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505349A5 JP2011505349A5 JP2010535473A JP2010535473A JP2011505349A5 JP 2011505349 A5 JP2011505349 A5 JP 2011505349A5 JP 2010535473 A JP2010535473 A JP 2010535473A JP 2010535473 A JP2010535473 A JP 2010535473A JP 2011505349 A5 JP2011505349 A5 JP 2011505349A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- strain
- composition
- bacteria
- mast cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 23
- 210000003630 histaminocyte Anatomy 0.000 claims 16
- 241000894006 Bacteria Species 0.000 claims 9
- 230000001580 bacterial effect Effects 0.000 claims 8
- 230000020411 cell activation Effects 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 241000186012 Bifidobacterium breve Species 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 241000194036 Lactococcus Species 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000006166 lysate Substances 0.000 claims 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 claims 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims 1
- 244000199866 Lactobacillus casei Species 0.000 claims 1
- 235000013958 Lactobacillus casei Nutrition 0.000 claims 1
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 claims 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 claims 1
- 239000003710 calcium ionophore Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims 1
- 229940017800 lactobacillus casei Drugs 0.000 claims 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291431A EP2065048A1 (en) | 2007-11-30 | 2007-11-30 | Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation |
| PCT/IB2008/003690 WO2009068997A1 (en) | 2007-11-30 | 2008-12-01 | Use of a l. casei strain, for the preparation of a composition for inhibiting mast cell activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011505349A JP2011505349A (ja) | 2011-02-24 |
| JP2011505349A5 true JP2011505349A5 (https=) | 2012-01-26 |
Family
ID=39323735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010535473A Pending JP2011505349A (ja) | 2007-11-30 | 2008-12-01 | 肥満細胞活性化の阻害用組成物を製造するためのエル・カゼイ株の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100284973A1 (https=) |
| EP (2) | EP2065048A1 (https=) |
| JP (1) | JP2011505349A (https=) |
| CN (1) | CN101909643A (https=) |
| AR (1) | AR069520A1 (https=) |
| RU (1) | RU2010126596A (https=) |
| WO (1) | WO2009068997A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2924307B1 (fr) * | 2007-12-04 | 2010-08-27 | Gervais Danone Sa | Utilisation de l. casei ssp. paracasei comme antifongique |
| WO2010013143A2 (en) * | 2008-08-01 | 2010-02-04 | Institut Pasteur | Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus |
| US20130121976A1 (en) * | 2010-03-12 | 2013-05-16 | Agusti Montserrat Carreras | Lactic Acid Bacteria for Coeliac Disease |
| KR101275227B1 (ko) * | 2010-10-13 | 2013-06-18 | 광주과학기술원 | 중증근무력증 예방, 개선 또는 치료용 조성물 |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CN103257237B (zh) * | 2013-05-09 | 2015-05-20 | 中国农业大学 | 一种食品中过敏原的体外检测方法 |
| SG11201704814SA (en) | 2014-12-23 | 2017-07-28 | 4D Pharma Res Ltd | Pirin polypeptide and immune modulation |
| WO2016102950A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Immune modulation |
| HRP20191949T1 (hr) | 2015-06-15 | 2020-01-24 | 4D Pharma Research Limited | Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti |
| ME03511B (me) * | 2015-06-15 | 2020-04-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| HK1254843B (zh) | 2015-11-20 | 2020-04-17 | 希杰生物科技株式会社 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN109312297B (zh) * | 2015-12-11 | 2022-09-23 | 精密生物集团有限公司 | 用于治疗肥胖症和相关代谢病的干酪乳杆菌 |
| SG10201913557TA (en) | 2016-03-04 | 2020-02-27 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| ES2877726T3 (es) | 2017-05-22 | 2021-11-17 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| TWI812624B (zh) | 2017-06-14 | 2023-08-21 | 南韓商希杰生物科技股份有限公司 | 包含細菌品系之組成物 |
| PL3600363T3 (pl) | 2017-06-14 | 2021-06-14 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| ES2841902T3 (es) | 2017-06-14 | 2021-07-12 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| EP3738599B1 (en) * | 2018-01-12 | 2023-12-27 | GI Innovation, Inc. | Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof |
| CN109266584B (zh) * | 2018-10-18 | 2020-09-08 | 扬州大学 | 一株具有肥大细胞活性调节作用的纤毛型鼠李糖乳杆菌及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2617758B2 (ja) * | 1988-03-25 | 1997-06-04 | 株式会社ヤクルト本社 | 抗体産生増強型免疫賦活剤 |
| CN1099271A (zh) * | 1993-08-23 | 1995-03-01 | 王世荣 | 生态口服液 |
| CN1114354A (zh) * | 1994-06-23 | 1996-01-03 | 江苏省纺织(集团)总公司实业开发分公司 | 双歧杆菌在含中药培养基中进行有氧发酵的方法 |
| AUPQ415899A0 (en) * | 1999-11-19 | 1999-12-16 | Vasse Research Institute Pty Ltd | Compositions for and methods of treatment of allergic diseases |
| JP4580542B2 (ja) * | 2000-05-17 | 2010-11-17 | 株式會社バイオニア | 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物 |
| PE20030283A1 (es) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| US20030092163A1 (en) * | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| CN1289092C (zh) * | 2002-10-29 | 2006-12-13 | 西安大鹏生物科技股份有限公司 | 一种肠道微生态调节剂 |
| FR2848115B1 (fr) * | 2002-12-05 | 2005-03-25 | Rhodia Chimie Sa | Composition de bacteries et son utilisation |
| DK1675481T3 (da) * | 2003-10-24 | 2009-01-19 | Nutricia Nv | Synbiotisk præparat til börn |
| CN100396771C (zh) * | 2004-05-10 | 2008-06-25 | 景岳生物科技股份有限公司 | 新的微生物株类干酪乳杆菌gm-080及其治疗过敏相关疾病的用途 |
| US7351572B2 (en) * | 2004-10-15 | 2008-04-01 | Genmont Biotech Inc. | Microorganism strain GM-090 of Lactobacillus fermentum and its use for stimulating IFN-γ secretion and/or treating allergy |
| EP1683425A1 (en) * | 2005-01-21 | 2006-07-26 | Compagnie Gervais Danone | Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction |
| WO2007035057A1 (en) * | 2005-09-23 | 2007-03-29 | Gwangju Institute Of Science And Technology | Composition for preventing or treating artritis comprising lactic acid bacteria and collangen as active ingredients |
| CN100556414C (zh) * | 2005-10-14 | 2009-11-04 | 德阳创新生物工程有限公司 | 一种具免疫调节功能的多菌组合物及其制备方法与用途 |
| JP2007117031A (ja) * | 2005-10-31 | 2007-05-17 | Nakagaki Gijutsushi Jimusho:Kk | インターフェロンガンマ発現誘導作用を有する発酵乳、及び発酵乳製造用種菌 |
-
2007
- 2007-11-30 EP EP07291431A patent/EP2065048A1/en not_active Withdrawn
-
2008
- 2008-12-01 JP JP2010535473A patent/JP2011505349A/ja active Pending
- 2008-12-01 EP EP08854776A patent/EP2224936A1/en not_active Withdrawn
- 2008-12-01 RU RU2010126596/15A patent/RU2010126596A/ru unknown
- 2008-12-01 WO PCT/IB2008/003690 patent/WO2009068997A1/en not_active Ceased
- 2008-12-01 US US12/745,079 patent/US20100284973A1/en not_active Abandoned
- 2008-12-01 AR ARP080105236A patent/AR069520A1/es unknown
- 2008-12-01 CN CN200880124467XA patent/CN101909643A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505349A5 (https=) | ||
| RU2010126596A (ru) | ПРИМЕНЕНИЕ ШТАММА L. casei ДЛЯ ПОЛУЧЕНИЯ КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ АКТИВАЦИИ ТУЧНЫХ КЛЕТОК | |
| Salazar et al. | Production of exopolysaccharides by Lactobacillus and Bifidobacterium strains of human origin, and metabolic activity of the producing bacteria in milk | |
| Esteban‐Fernández et al. | In vitro beneficial effects of Streptococcus dentisani as potential oral probiotic for periodontal diseases | |
| Harty et al. | Pathogenic potential of lactobacilli | |
| Balamurugan et al. | Molecular studies of fecal anaerobic commensal bacteria in acute diarrhea in children | |
| Lloyd-Price et al. | The healthy human microbiome | |
| Yli‐Knuuttila et al. | Colonization of Lactobacillus rhamnosus GG in the oral cavity | |
| Balamurugan et al. | Probiotic potential of lactic acid bacteria present in home made curd in southern India | |
| Psomas et al. | Assimilation of cholesterol by yeast strains isolated from infant feces and Feta cheese | |
| Orlando et al. | Antiproliferative and proapoptotic effects of viable or heat-killed Lactobacillus paracasei IMPC2. 1 and Lactobacillus rhamnosus GG in HGC-27 gastric and DLD-1 colon cell lines | |
| Saarela et al. | Influence of fermentation time, cryoprotectant and neutralization of cell concentrate on freeze‐drying survival, storage stability, and acid and bile exposure of Bifidobacterium animalis ssp. lactis cells produced without milk‐based ingredients | |
| Chang et al. | Probiotic characteristics of lactic acid bacteria isolated from kimchi | |
| Yadav et al. | Adhesion of lactobacilli and their anti-infectivity potential | |
| Endo et al. | Bifidobacterium reuteri sp. nov., Bifidobacterium callitrichos sp. nov., Bifidobacterium saguini sp. nov., Bifidobacterium stellenboschense sp. nov. and Bifidobacterium biavatii sp. nov. isolated from faeces of common marmoset (Callithrix jacchus) and red-handed tamarin (Saguinus midas) | |
| Fernandez et al. | Growth, acid production and bacteriocin production by probiotic candidates under simulated colonic conditions | |
| Montesi et al. | Molecular and microbiological analysis of caecal microbiota in rats fed with diets supplemented either with prebiotics or probiotics | |
| Gerritsen | The genus Romboutsia: genomic and functional characterization of novel bacteria dedicated to life in the intestinal tract | |
| SI3048165T1 (en) | NEW SEV BACTERIA BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS CECT 8145 AND ITS APPLICATION FOR INJURY AND / OR PREVENTION OF OVERVIEW OF BODY WEALTH AND BALANCE AND ASSOCIATED DISEASES | |
| Kitazawa et al. | Probiotics: immunobiotics and immunogenics | |
| Fhoula et al. | Functional probiotic assessment and in vivo cholesterol‐lowering efficacy of Weissella sp. associated with arid lands living‐hosts | |
| Ziar et al. | Effect of prebiotic carbohydrates on growth, bile survival and cholesterol uptake abilities of dairy‐related bacteria | |
| RU2011124924A (ru) | Штамм lactobacillus delbrueckii, снижающий содержание холестерина в крови | |
| JP2006273852A5 (https=) | ||
| Zanini et al. | The effects of fermented milks with simple and complex probiotic mixtures on the intestinal microbiota and immune response of healthy adults and children |